| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J S Perlmutter, S M Moerlei. PET measurements of dopaminergic pathways in the brain. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). vol 43. issue 2. 1999-08-18. PMID:10429509. |
positron emission tomography (pet) measurements of dopaminergic pathways have revealed several new insights into the role of dopamine in the pathophysiology and pharmacology of brain diseases such as parkinson's disease (pd), dystonia and schizophrenia. |
1999-08-18 |
2023-08-12 |
Not clear |
| T Nagatsu, H Ichinos. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Molecular neurobiology. vol 19. issue 1. 1999-06-14. PMID:10321973. |
the intracellular concentrations of bh4, which are mainly determined by gch activity, may regulate the activity of th (an enzyme-synthesizing catecholamines from tyrosine), tph (an enzyme-synthesizing serotonin and melatonin from tryptophan), pah (an enzyme required for complete degradation of phenylalanine to tyrosine, finally to co2 + h2o), and also the activity of nos (an enzyme forming no from arginine), dominantly inherited hereditary progressive dystonia (hpd), also termed dopa-responsive dystonia (drd) or segawa's disease, is a dopamine deficiency in the nigrostriatal dopamine neurons, and is caused by mutations of one allele of the gch gene. |
1999-06-14 |
2023-08-12 |
Not clear |
| T Nagatsu, H Ichinos. Molecular biology of catecholamine-related enzymes in relation to Parkinson's disease. Cellular and molecular neurobiology. vol 19. issue 1. 1999-06-04. PMID:10079965. |
mutations of gch result in reductions in gch activity, bh4, th activity, and dopamine, causing either recessively inherited gch deficiency or dominantly inherited hereditary progressive dystonia [hpd; segawa's disease; also called dopa-responsive dystonia (drd)]. |
1999-06-04 |
2023-08-12 |
Not clear |
| R D Todd, J S Perlmutte. Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition. Molecular neurobiology. vol 16. issue 2. 1999-05-21. PMID:9588625. |
mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine d2 receptor inhibition. |
1999-05-21 |
2023-08-12 |
mouse |
| R D Todd, J S Perlmutte. Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition. Molecular neurobiology. vol 16. issue 2. 1999-05-21. PMID:9588625. |
we recently proposed that hypofunction of dopamine d2 receptor-mediated inhibition of the indirect output pathway of the basal ganglia can result in dystonia. |
1999-05-21 |
2023-08-12 |
mouse |
| R D Todd, J S Perlmutte. Mutational and biochemical analysis of dopamine in dystonia: evidence for decreased dopamine D2 receptor inhibition. Molecular neurobiology. vol 16. issue 2. 1999-05-21. PMID:9588625. |
recently, several genetic-linkage locations have been identified for early-onset dystonia and for two of these loci, mutations decreasing dopamine synthesis have been demonstrated. |
1999-05-21 |
2023-08-12 |
mouse |
| M Gernert, A Richter, W Lösche. Alterations in spontaneous single unit activity of striatal subdivisions during ontogenesis in mutant dystonic hamsters. Brain research. vol 821. issue 2. 1999-04-13. PMID:10064814. |
previous autoradiographic studies in the dtsz hamster revealed a decreased dopamine d1 and d2 receptor binding and an increased [3h]-2-deoxyglucose uptake in the dorsomedial caudate-putamen (cpu), a region supposed to be critically involved in dystonia. |
1999-04-13 |
2023-08-12 |
Not clear |
| T Kondo, K Otani, N Tokinaga, M Ishida, N Yasui, S Kanek. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. Journal of clinical psychopharmacology. vol 19. issue 1. 1999-04-07. PMID:9934942. |
characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. |
1999-04-07 |
2023-08-12 |
Not clear |
| T Kondo, K Otani, N Tokinaga, M Ishida, N Yasui, S Kanek. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. Journal of clinical psychopharmacology. vol 19. issue 1. 1999-04-07. PMID:9934942. |
the occurrence of acute dystonia was prospectively monitored in 39 schizophrenic patients (18 male and 21 female) treated with 9 to 27 mg/day of nemonapride, a selective dopamine antagonist, and the relationship of acute dystonia with characteristics of patients and plasma concentrations of the drug and prolactin was investigated. |
1999-04-07 |
2023-08-12 |
Not clear |
| T Kondo, K Otani, N Tokinaga, M Ishida, N Yasui, S Kanek. Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist. Journal of clinical psychopharmacology. vol 19. issue 1. 1999-04-07. PMID:9934942. |
prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride. |
1999-04-07 |
2023-08-12 |
Not clear |
| M Madsen, H Lubli. MK-801-induced dystonia in cebus monkeys. Clinical neuropharmacology. vol 21. issue 6. 1999-02-12. PMID:9844788. |
dystonia induced by dopamine d1 and d2 antagonists is easily antagonized by biperiden and dopamine agonists, whereas these drugs had no significant effect on mk-801-induced dystonia. |
1999-02-12 |
2023-08-12 |
monkey |
| G Künig, K L Leenders, A Antonini, P Vontobel, A Weindl, H M Meinc. D2 receptor binding in dopa-responsive dystonia. Annals of neurology. vol 44. issue 5. 1998-12-02. PMID:9818931. |
we have studied dopamine d2 receptor binding by [11c]raclopride positron emission tomography in 14 patients with dopa-responsive dystonia (drd). |
1998-12-02 |
2023-08-12 |
Not clear |
| B S Jeon, J M Jeong, S S Park, M C Le. Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. Advances in neurology. vol 78. 1998-11-17. PMID:9750927. |
dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. |
1998-11-17 |
2023-08-12 |
Not clear |
| E S Molho, P J Feustel, S A Facto. Clinical comparison of tardive and idiopathic cervical dystonia. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 3. 1998-08-10. PMID:9613742. |
it has been suggested that tardive cervical dystonia may be clinically indistinguishable from the idiopathic form and that the diagnosis rests solely on documenting an exposure to dopamine antagonist medications. |
1998-08-10 |
2023-08-12 |
Not clear |
| E S Molho, P J Feustel, S A Facto. Clinical comparison of tardive and idiopathic cervical dystonia. Movement disorders : official journal of the Movement Disorder Society. vol 13. issue 3. 1998-08-10. PMID:9613742. |
these differences may help to distinguish them in the clinical setting, improve diagnostic accuracy, and support the existence of a causal relationship between exposure to dopamine antagonist medications and chronic dystonia. |
1998-08-10 |
2023-08-12 |
Not clear |
| P N Van Harte. [Acute dystonia]. Nederlands tijdschrift voor geneeskunde. vol 141. issue 30. 1998-06-25. PMID:9542880. |
the mechanism underlying acute dystonia is unknown: both increase and decrease of the striatal dopamine transmission have been put forward as possible causes. |
1998-06-25 |
2023-08-12 |
Not clear |
| B S Jeon, J M Jeong, S S Park, J M Kim, Y S Chang, H C Song, K M Kim, K Y Yoon, M C Lee, S B Le. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Annals of neurology. vol 43. issue 6. 1998-06-25. PMID:9629849. |
dopamine transporter density measured by [123i]beta-cit single-photon emission computed tomography is normal in dopa-responsive dystonia. |
1998-06-25 |
2023-08-12 |
human |
| M Hallet. The neurophysiology of dystonia. Archives of neurology. vol 55. issue 5. 1998-06-09. PMID:9605716. |
the defect is in guanosine triphosphate cyclohydrolase i, a gene that makes a cofactor for the synthesis of dopamine, which explains why this form of dystonia should be amenable to treatment with levodopa. |
1998-06-09 |
2023-08-12 |
Not clear |
| M Hallet. The neurophysiology of dystonia. Archives of neurology. vol 55. issue 5. 1998-06-09. PMID:9605716. |
another example of dystonia in which a disorder of dopamine pharmacology appears responsible is the dystonia occurring in parkinson disease, either spontaneously or as a result of treatment. |
1998-06-09 |
2023-08-12 |
Not clear |
| M Hallet. The neurophysiology of dystonia. Archives of neurology. vol 55. issue 5. 1998-06-09. PMID:9605716. |
curiously, the dystonia occurs at both peak and trough dopamine levels. |
1998-06-09 |
2023-08-12 |
Not clear |